Two Sigma Securities’s VistaGen Therapeutics VTGN Stock Holding History

Two Sigma Securities’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.43K	Buy	+16,495	New	+$10K	﹤0.01%	1471
2023 Q2	–	Sell	-1,165	Closed	-$4.36K	–	3404
2023 Q1	$4.36K	Sell	1,165 -398	-25%	-$2.09K	﹤0.01%	2536
2022 Q4	$4.83K	Sell	1,563 -374	-19%	-$1.41K	﹤0.01%	2455
2022 Q3	$9K	Buy	+1,937	New	+$19.2K	﹤0.01%	2420
2021 Q2	–	Sell	-430	Closed	-$27K	–	1740
2021 Q1	$27K	Buy	+430	New	+$28.7K	﹤0.01%	766
2020 Q1	–	Sell	-2,441	Closed	-$51K	–	2382
2019 Q4	$51K	Buy	+2,441	New	+$61.7K	﹤0.01%	2235

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Securities's VTGN Position: Q1 2026 in Review

Two Sigma Securities opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 16,495 shares worth $9.43K. The stake represents ﹤0.01% of the portfolio and ranks #1471 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in VTGN as recently as Q1 2023.

Two Sigma Securities first reported a position in VTGN in Q4 2019 and has held it in 6 quarters since. The position peaked at $51K in Q4 2019. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Two Sigma Securities held 16,495 shares of VistaGen Therapeutics worth $9.43K as of Q1 2026.
VistaGen Therapeutics was a new Two Sigma Securities position in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1471 holding.
Two Sigma Securities first reported a position in VistaGen Therapeutics in Q4 2019 and has held it in 6 quarters since.
Two Sigma Securities's VistaGen Therapeutics position peaked at $51K in Q4 2019.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.